Federico M Goodsaid
Overview
Explore the profile of Federico M Goodsaid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1240
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goodsaid F
Clin Transl Sci
. 2019 Jun;
12(5):431-439.
PMID: 31162800
The evolution of chemistries and instrument platforms for next-generation sequencing has led to sequencing of genomic variants in both tumor biopsies as well as in circulating tumor cells (CTCs) and...
2.
Goodsaid F, Frueh F, Mattes W
Drug Discov Today Technol
. 2014 Jul;
4(2):47-50.
PMID: 24980840
The qualification of biomarkers of drug safety requires data on many compounds and nonclinical and clinical studies. The cost and effort associated with these qualifications cannot be easily covered by...
3.
Goodsaid F, Frueh F
Drug Discov Today Technol
. 2014 Jul;
4(1):9-11.
PMID: 24980714
The FDA has developed a Pilot Process for Biomarker Qualification. Initial experience with this process has underscored the care that a long-term approach to biomarker qualification independently of development for...
4.
Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop
Bai J, Bell R, Buckman S, Burckart G, Eichler H, Fang K, et al.
AAPS J
. 2011 Mar;
13(2):274-83.
PMID: 21448748
There have been some successes in qualifying biomarkers and applying them to drug development and clinical treatment of various diseases. A recent success is illustrated by a collaborative effort among...
5.
Goodsaid F, Mendrick D
Sci Transl Med
. 2010 Sep;
2(47):47ps44.
PMID: 20811041
The gap between development of exploratory biomarkers and their acceptance in drug development and regulatory review is a hurdle in the development of better therapies. The U.S. Food and Drug...
6.
Shi L, Campbell G, Jones W, Campagne F, Wen Z, Walker S, et al.
Nat Biotechnol
. 2010 Aug;
28(8):827-38.
PMID: 20676074
Gene expression data from microarrays are being applied to predict preclinical and clinical endpoints, but the reliability of these predictions has not been established. In the MAQC-II project, 36 independent...
7.
Goodsaid F, Amur S, Aubrecht J, Burczynski M, Carl K, Catalano J, et al.
Nat Rev Drug Discov
. 2010 Jun;
9(6):435-45.
PMID: 20514070
Heterogeneity in the underlying mechanisms of disease processes and inter-patient variability in drug responses are major challenges in drug development. To address these challenges, biomarker strategies based on a range...
8.
9.
Shi L, Jones W, Jensen R, Harris S, Perkins R, Goodsaid F, et al.
BMC Bioinformatics
. 2008 Sep;
9 Suppl 9:S10.
PMID: 18793455
Background: Reproducibility is a fundamental requirement in scientific experiments. Some recent publications have claimed that microarrays are unreliable because lists of differentially expressed genes (DEGs) are not reproducible in similar...
10.
Weaver J, Snyder R, Knapton A, Herman E, Honchel R, Miller T, et al.
Toxicol Pathol
. 2008 Sep;
36(6):840-9.
PMID: 18776166
Drug-associated vascular injury can be caused by phosphodiesterase (PDE) IV inhibitors and drugs from several other classes. The pathogenesis is poorly understood, but it appears to include vascular and innate...